局部晚期或转移性尿路上皮癌-话题@MedSci

#局部晚期或转移性尿路上皮癌#

7篇内容 | 754人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1700460, encodeId=8cf91e00460f4, content=<a href='/topic/show?id=a3094e618fc' target=_blank style='color:#2F92EE;'>#局部晚期或转移性尿路上皮癌#</a>, objectTitle=Eur Urol：恩福单抗维多汀治疗局部晚期或转移性尿路上皮癌的疗效如何？, objectType=article, longId=299913, objectId=686d29991338, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=686d29991338, replyNumber=0, likeNumber=38, createdTime=2022-04-06, rootId=0, userName=dinorsor534, userId=905730099938, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=686d29991338, moduleTitle=Eur Urol：恩福单抗维多汀治疗局部晚期或转移性尿路上皮癌的疗效如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=686d29991338)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1700458, encodeId=88771e00458dd, content=<a href='/topic/show?id=a3094e618fc' target=_blank style='color:#2F92EE;'>#局部晚期或转移性尿路上皮癌#</a>, objectTitle=Eur Urol：铂治疗的局部晚期或转移性尿路上皮癌患者的Atezolizumab与化疗治疗比较 , objectType=article, longId=211015, objectId=27af21101554, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27af21101554, replyNumber=0, likeNumber=32, createdTime=2021-07-22, rootId=0, userName=dinorsor534, userId=905730099938, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27af21101554, moduleTitle=Eur Urol：铂治疗的局部晚期或转移性尿路上皮癌患者的Atezolizumab与化疗治疗比较 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27af21101554)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1700459, encodeId=2d7c1e0045997, content=<a href='/topic/show?id=a3094e618fc' target=_blank style='color:#2F92EE;'>#局部晚期或转移性尿路上皮癌#</a>, objectTitle=Lancet oncol：Enfortumab vedotin用于抗PD-1治疗后的铂不适用的局部晚期或转移性尿路上皮癌的疗效可期！, objectType=article, longId=211335, objectId=282e211335e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=282e211335e4, replyNumber=0, likeNumber=45, createdTime=2022-03-24, rootId=0, userName=dinorsor534, userId=905730099938, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=282e211335e4, moduleTitle=Lancet oncol：Enfortumab vedotin用于抗PD-1治疗后的铂不适用的局部晚期或转移性尿路上皮癌的疗效可期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=282e211335e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1700457, encodeId=70bc1e004578c, content=<a href='/topic/show?id=a3094e618fc' target=_blank style='color:#2F92EE;'>#局部晚期或转移性尿路上皮癌#</a>, objectTitle=默克和辉瑞的抗PD-L1单抗Bavencio改善了局部晚期或转移性尿路上皮癌患者的生存率：III期临床达到主要终点, objectType=article, longId=185843, objectId=5f5518584350, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f5518584350, replyNumber=0, likeNumber=34, createdTime=2020-06-15, rootId=0, userName=dinorsor534, userId=905730099938, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f5518584350, moduleTitle=默克和辉瑞的抗PD-L1单抗Bavencio改善了局部晚期或转移性尿路上皮癌患者的生存率：III期临床达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f5518584350)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1700456, encodeId=79d31e0045698, content=<a href='/topic/show?id=a3094e618fc' target=_blank style='color:#2F92EE;'>#局部晚期或转移性尿路上皮癌#</a>, objectTitle=Seattle Genetics和Astellas的抗体偶联药物enfortumab vedotin治疗局部晚期或转移性尿路上皮癌，喜获FDA的优先审查, objectType=article, longId=179625, objectId=df171e962513, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df171e962513, replyNumber=0, likeNumber=40, createdTime=2020-08-12, rootId=0, userName=dinorsor534, userId=905730099938, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df171e962513, moduleTitle=Seattle Genetics和Astellas的抗体偶联药物enfortumab vedotin治疗局部晚期或转移性尿路上皮癌，喜获FDA的优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df171e962513)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1700455, encodeId=9ead1e0045550, content=<a href='/topic/show?id=a3094e618fc' target=_blank style='color:#2F92EE;'>#局部晚期或转移性尿路上皮癌#</a>, objectTitle=JAMA Oncol： Durvalumab在局部晚期或转移性尿路上皮癌中疗效如何？, objectType=article, longId=110698, objectId=81a911069830, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=81a911069830, replyNumber=0, likeNumber=38, createdTime=2017-10-18, rootId=0, userName=dinorsor534, userId=905730099938, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=81a911069830, moduleTitle=JAMA Oncol： Durvalumab在局部晚期或转移性尿路上皮癌中疗效如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=81a911069830)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1700454, encodeId=82631e0045468, content=<a href='/topic/show?id=a3094e618fc' target=_blank style='color:#2F92EE;'>#局部晚期或转移性尿路上皮癌#</a>, objectTitle=lancet oncol：派姆单抗（pembrolizumab）在局部晚期或转移性尿路上皮癌患者中安全性和活性的1期临床研究(KEYNOTE-012), objectType=article, longId=87698, objectId=f06c8e69880, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f06c8e69880, replyNumber=0, likeNumber=30, createdTime=2017-11-27, rootId=0, userName=dinorsor534, userId=905730099938, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f06c8e69880, moduleTitle=lancet oncol：派姆单抗（pembrolizumab）在局部晚期或转移性尿路上皮癌患者中安全性和活性的1期临床研究(KEYNOTE-012), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f06c8e69880)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

局部晚期或转移性尿路上皮癌

2020-05-29

dinorsor534 (审核中...)

前往app查看评论内容

#局部晚期或转移性尿路上皮癌#

Eur Urol：恩福单抗维多汀治疗局部晚期或转移性尿路上皮癌的疗效如何？

2022-04-06

dinorsor534 (审核中...)

前往app查看评论内容

#局部晚期或转移性尿路上皮癌#

Eur Urol：铂治疗的局部晚期或转移性尿路上皮癌患者的Atezolizumab与化疗治疗比较

2021-07-22

dinorsor534 (审核中...)

前往app查看评论内容

#局部晚期或转移性尿路上皮癌#

Lancet oncol：Enfortumab vedotin用于抗PD-1治疗后的铂不适用的局部晚期或转移性尿路上皮癌的疗效可期！

2022-03-24

dinorsor534 (审核中...)

前往app查看评论内容

#局部晚期或转移性尿路上皮癌#

默克和辉瑞的抗PD-L1单抗Bavencio改善了局部晚期或转移性尿路上皮癌患者的生存率：III期临床达到主要终点

2020-06-15

dinorsor534 (审核中...)

前往app查看评论内容

#局部晚期或转移性尿路上皮癌#

Seattle Genetics和Astellas的抗体偶联药物enfortumab vedotin治疗局部晚期或转移性尿路上皮癌，喜获FDA的优先审查

2020-08-12

dinorsor534 (审核中...)

前往app查看评论内容

#局部晚期或转移性尿路上皮癌#

JAMA Oncol： Durvalumab在局部晚期或转移性尿路上皮癌中疗效如何？

2017-10-18

dinorsor534 (审核中...)

前往app查看评论内容

#局部晚期或转移性尿路上皮癌#

lancet oncol：派姆单抗（pembrolizumab）在局部晚期或转移性尿路上皮癌患者中安全性和活性的1期临床研究(KEYNOTE-012)

2017-11-27

科室
- - 订阅+
  - 更多科室
工具
服务